CLDXのチャート
CLDXの企業情報
| symbol | CLDx |
|---|---|
| 会社名 | Celldex Therapeutics Inc. （セルデックス・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: In Vitro_In Vivo Diagnostic Substances |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 セルデックス・セラピューティクス（Celldex Therapeutics Inc.）はバイオ医薬品会社である。同社はがんおよび他の疾患の治療のためのいくつかの免疫療法技術の開発・商業化に従事する。主薬のリンテカ（リンドペピムートおよびCDX-110とも呼ばれる）は、神経膠芽腫患者の治療のための治療的ワクチンである。そのグレムバツムマブベドチン（CDX-011とも呼ばれる）は、転移性メラノーマの治療のためのものである。バリルマブ（CDX-1127とも呼ばれる）は、免疫調節抗体である。臨床開発における早期段階の薬剤候補には、癌の適応症のための抗原提示細胞（APC）および免疫細胞動員剤および樹状細胞増殖因子であるCDX-301を標的とする標的免疫療法剤であるCDX-1401が含まれる。同社は多面的腫瘍関連マクロファージ（TAM）プログラムを含む。同社のパイプラインには、ヒト化モノクローナル抗体であるCDX-0158とCDX-3379を含む。 セルデックス・セラピュ―ティクスは、米国のバイオ医薬品企業。癌および治療が困難な疾患のための免疫療法技術の開発と商業化に従事する。薬剤候補は、｢Rindopepimut(CDX-110)｣免疫療法に標的を当てる、｢Glembatumumab vedotin (CDX-011)｣トリプルネガティブ乳癌治療のための薬などがある。 Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. |
| 本社所在地 | Perryville III Building 53 Frontage Road Suite 220 Hampton NJ 08827 USA |
| 代表者氏名 | Larry Ellberger ラリー・エルバーガー |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 908-200-7500 |
| 設立年月日 | 30651 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 197人 |
| url | www.celldex.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cldx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -66.64400 |
| 終値（lastsale） | 0.4326 |
| 時価総額（marketcap） | 70272552.8232 |
| 時価総額 | 時価総額（百万ドル） 67.41357 |
| 売上高 | 売上高（百万ドル） 14.21100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -46.59543 |
| 当期純利益 | 当期純利益（百万ドル） -183.84300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Celldex Therapeutics Inc. revenues increased 27% to $6.8M. Net loss increased from $62.8M to $134.5M. Revenues reflect Revenue Sales of Goods_Services increase from $1.3M to $2.7M Contracts and Grants increase of 1% to $4.2M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.51 to -$0.95. |
CLDXのテクニカル分析
CLDXのニュース
Celldex Therapeutics (CLDX) Presents At AAAAI Conference 2023/03/02 18:16:28 Seeking Alpha
The following slide deck was published by Celldex Therapeutics, Inc.
Celldex: Q4 Earnings Snapshot 2023/02/28 23:35:05 WTOP
HAMPTON, N.J. (AP) — HAMPTON, N.J. (AP) — Celldex Therapeutics Inc. (CLDX) on Tuesday reported a loss of $26.5 million…
Celldex GAAP EPS of -$0.56 beats by $0.03, revenue of $1.61M beats by $1.35M 2023/02/28 22:19:58 Seeking Alpha
Celldex press release (CLDX): Q4 GAAP EPS of -$0.56 beats by $0.03.Revenue of $1.61M (+387.9% Y/Y) beats by $1.35M.Cash, cash equivalents and marketable securities as of December…
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update 2023/02/28 21:01:00 GlobeNewswire
- Phase 1b multi-dose CSU data presented at AAAAI on February 26 - - Phase 2 CSU enrollment completion expected by Q3 2023 -
CLDX stock gains on Phase 1 data for urticaria candidate (NASDAQ:CLDX) 2023/02/27 15:42:51 Seeking Alpha
Celldex Therapeutics (CLDX) added ~12%after the biotech announced early-stage results for its experimental urticaria therapy barzolvolimab. Read the full story here.
Celldex Therapeutics Inc. (CLDX) Looks Set To Grow At A Great Clip In 2022 2022/04/06 12:00:00 Marketing Sentinel
Celldex Therapeutics Inc. (NASDAQ:CLDX) has a beta value of 2.76 and has seen 1.18 million shares traded in the last trading session. The company, currently valued at $1.68B, closed the last trade at $36.04 per share which meant it lost -$0.66 on the day or -1.80% during that session. The CLDX stock price is -58.71% … Celldex Therapeutics Inc. (CLDX) Looks Set To Grow At A Great Clip In 2022 Read More »
Celldex Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation 2022/03/01 06:12:51 Seeking Alpha
Celldex Therapeutics, Inc. (CLDX) CEO Anthony Marucci on Q4 2021 Results - Earnings Call Transcript 2022/03/01 01:57:16 Seeking Alpha
Celldex GAAP EPS of -$0.43 misses by $0.02, revenue of $0.33M misses by $0.84M (NASDAQ:CLDX) 2022/02/28 21:02:32 Seeking Alpha
Celldex press release (NASDAQ:CLDX): Q4 GAAP EPS of -$0.43 misses by $0.02.Revenue of $0.33M (-91.3% Y/Y) misses by $0.84M.
Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update 2022/02/28 21:01:00 GlobeNewswire
HAMPTON, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.
Celldex Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation 2022/03/01 06:12:51 Seeking Alpha
Celldex Therapeutics, Inc. (CLDX) CEO Anthony Marucci on Q4 2021 Results - Earnings Call Transcript 2022/03/01 01:57:16 Seeking Alpha
Celldex GAAP EPS of -$0.43 misses by $0.02, revenue of $0.33M misses by $0.84M (NASDAQ:CLDX) 2022/02/28 21:02:32 Seeking Alpha
Celldex press release (NASDAQ:CLDX): Q4 GAAP EPS of -$0.43 misses by $0.02.Revenue of $0.33M (-91.3% Y/Y) misses by $0.84M.
Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update 2022/02/28 21:01:00 GlobeNewswire
HAMPTON, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.